Medicare's $50 obesity drug program gains rapid traction at major drugstores

On July 1st, Medicare quietly crossed a threshold it had long avoided — acknowledging obesity not as a lifestyle choice but as a medical condition worthy of coverage. The Bridge program, offering GLP-1 weight-loss medications to eligible beneficiaries for fifty dollars a month, met a demand that had been building in silence: within weeks, two major pharmacy chains had each filled over one hundred thousand prescriptions. What the numbers reveal is less a story about drugs than about the distance between medical need and financial reach, and what becomes possible when that distance narrows.